top of page
Colorful Disks

Luciferase Reporter Cell Lines for Monitoring
TF Transactivation

Our Luciferase Reporter Stable cell lines are genetically engineered to express luciferase during the activation of specific Transcription Factors (TFs) Binding and Activation to provide an efficient approach to study and monitor various cellular processes, including gene regulation and signaling pathways.

We offer a wide selection of validated Firefly luciferase reporter cell lines that measure transcription factor activity as a read-out for various signaling pathways.

We also offer Gaussia luciferase reporter cell lines, a special type of luciferase that is naturally secreted from cells, which allows for the easy measurement of reporter activity directly in the media without any need to harvest the cells. 

 

Principle

Signosis’ luciferase reporter cell lines are engineered to sensitively and specifically monitor transcription factor (TF) activity in live cells. Each stable line is built using a proprietary enhancer construct containing multiple tandem repeats of TF-specific cis-regulatory elements — ensuring high inducibility with minimal basal expression.

To generate each line, cells are transfected with a TF-specific reporter vector containing a selection marker (Hygromycin or Neomycin). Following antibiotic selection, individual clones are screened for responsiveness and reproducibility. The most inducible and stable clone is selected and expanded for distribution.

Each cell line is rigorously tested to ensure accuracy, specificity, and reproducibility. 

The key aspects of validation and quality guarantees applied to all of our cell lines:

  • Consistent, functional reliability through 25–30 passages

  • High specificity to the target signaling pathway

  • Low background signal combined with strong inducibility

  • Mycoplasma‑free, identity‑verified, and morphologically monitored.

  • Compatibility with Firefly or Gaussia luciferase systems for flexible assay design

Firefly Luciferase (1).png
Gaussia diagram.png

Benefits

Validated & Quality Assured

All cell lines undergo rigorous validation to ensure accuracy, specificity, and reproducibility.

Stable and Reliable

Reporter expression and cellular behavior remain consistent across multiple passages and freeze-thaw cycles.

Ready-to-use

Cryopreserved cells are delivered assay-ready and can be revived and plated directly for experiments with minimal recovery time.

High Sensitivity & Proven Performance

Reporter cells produce a strong and measurable signal in response to stimulation, with reliable performance across multiple validation experiments.

Fully QC‑Screened

Certified mycoplasma-free and regularly monitored for morphology and health.

Optimized Detection

Compatible with our highly sensitive Luciferase Substrates for accurate and robust signal detection.

High Pathway Specificity

Confirmed through selective ligand stimulation; each cell line responds only to its target signaling pathway with limited to no cross-reactivity.

Backed by Data

A detailed Certificate of Analysis is available upon request, including assay results and QC metrics.

Customizable

We offer custom development of transcription factor (TF) reporter cell lines tailored to your specific pathway or research needs.

Signaling Pathways

Cell Lines

Androgen Receptor/ AR

Targeted therapies for prostate cancer and other androgen-related diseases.

Calcineurin/NFAT
T Cell Activation

Activation of T Cells in immune response via calcium signaling.

ER Stress/ATF4
ATF6/CHOP/ERSE

 

Development of treatments for type 2 diabetes and neurodegenerative disorders.

Glucocorticoid
Receptor/GR

Development of treatments for autoimmune and inflammatory diseases.

Hypoxia
HIF

Development of treatments for cancer and ischemic diseases.

Inflammation
NF-κB

Development of treatments for cancer, diabetes, and inflammation.

JAK/STAT1/2
IFNα/ISRE

Development of treatments for cancer and autoimmune disorders.

MAPK/ERK
ELK

Development of treatments for cancer and autoimmune disorders.

Metabolism
FXR/RAR/AARE

Development of drugs for treating various metabolic diseases, including liver disease and diabetes.

SMAD 2/3/4
TGF-β

Development of treatments for cancer and fibrosis.

Wnt/β-Catenin
TCF/LEF

Development of treatments for cancer and bone disorders.

Antioxidant Pathway/ NRF2

Development of treatments for Alzheimer's, Parkinson's, and cancer.

cAMP/PKA
CREB

Development of drugs for treating various diseases, including cancer, diabetes, and inflammation.

Estrogen
Receptor

Targeted therapies for breast cancer and other estrogen-related diseases.

Heavy Metal Stress
MRF

Development of treatments for heavy metal toxicity.

Immune Response
IRF

Development of treatments for autoimmune and inflammatory diseases.

JAK/STAT1
IFNgamma

Development of drugs for treating various diseases, including cancer and autoimmune disorders.

JAK/STAT3
 

Development of drugs for treating various diseases, including cancer and inflammation.

MAPK/JNK
AP-1

Development of drugs for treating various diseases, including cancer, diabetes, and inflammation.

DNA Damage
p53

Development of treatments for cancer and genetic disorders.

SMAD 1/5/8
BMP

Development of treatments for bone and cartilage disorders.

Xenobiotic Stress
Toxicity/XRE/AHR

Development of treatments for xenobiotic toxicity and related diseases.

Signaling Pathways

Browse

bottom of page